{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T11:35:31Z","timestamp":1777203331094,"version":"3.51.4"},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,2,1]]},"DOI":"10.1093\/ckj\/sfx125","type":"journal-article","created":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T19:13:42Z","timestamp":1507230822000},"page":"80-88","source":"Crossref","is-referenced-by-count":46,"title":["Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes"],"prefix":"10.1093","volume":"11","author":[{"given":"Luciano","family":"Pereira","sequence":"first","affiliation":[]},{"given":"Catarina","family":"Meng","sequence":"additional","affiliation":[]},{"given":"Daniela","family":"Marques","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o M","family":"Fraz\u00e3o","sequence":"additional","affiliation":[]}],"member":"286","published-online":{"date-parts":[[2017,12,8]]},"reference":[{"key":"key\n\t\t\t\t20180205012735_sfx125-B1","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0140-6736(13)60687-X","article-title":"Chronic kidney disease: global dimension and perspectives","volume":"382","author":"Jha","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B2","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)","volume":"113","year":"2009","journal-title":"Kidney Int Suppl"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B3","first-page":"835","article-title":"The role of fibroblast growth factor 23 in chronic kidney disease-mineral and bone disorder","volume":"33","author":"Diniz","year":"2013","journal-title":"Nefrologia"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B4","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.ki.5001514","article-title":"Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients","volume":"70","author":"Kalantar-Zadeh","year":"2006","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B5","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2215\/CJN.12941213","article-title":"Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study","volume":"10","author":"Tentori","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B6","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2215\/CJN.01060308","article-title":"Consistent control of mineral and bone disorder in incident hemodialysis patients","volume":"3","author":"Danese","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B7","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/sdi.12357","article-title":"The use of calcimimetics for the treatment of secondary hyperparathyroidism: a 10 year evidence review","volume":"28","author":"Rodriguez","year":"2015","journal-title":"Semin Dial"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B8","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.2174\/092986707782794096","article-title":"Calcium sensing receptor activators: calcimimetics","volume":"14","author":"Harrington","year":"2007","journal-title":"Curr Med Chem"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B9","doi-asserted-by":"crossref","first-page":"354","DOI":"10.2215\/CJN.05241008","article-title":"Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006","volume":"4","author":"St Peter","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B10","first-page":"i12","article-title":"Secondary hyperparathyroidism disease stabilization following calcimimetic therapy","volume":"1","author":"Frazao","year":"2008","journal-title":"NDT Plus"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B11","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1681\/ASN.2004060512","article-title":"Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study","volume":"16","author":"Lindberg","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B12","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B13","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s40265-016-0671-3","article-title":"Etelcalcetide: first global approval","volume":"76","author":"Blair","year":"2016","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B14","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1681\/ASN.V1341017","article-title":"The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism","volume":"13","author":"Goodman","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B15","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1523-1755.2005.67139.x","article-title":"Achieving NKF-K\/DOQI bone metabolism and disease treatment goals with cinacalcet HCl","volume":"67","author":"Moe","year":"2005","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B16","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.ajkd.2006.01.015","article-title":"Meta-analysis of biochemical and patient-level effects of calcimimetic therapy","volume":"47","author":"Strippoli","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B17","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1525-139X.2011.00935.x","article-title":"Does it matter how parathyroid hormone levels are suppressed in secondary hyperparathyroidism?","volume":"24","author":"Stubbs","year":"2011","journal-title":"Semin Dial"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B18","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.2215\/CJN.02110310","article-title":"Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism","volume":"5","author":"Komaba","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B19","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1001\/jama.2011.826","article-title":"Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease","volume":"305","author":"Isakova","year":"2011","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B20","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1681\/ASN.2006080936","article-title":"Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study","volume":"18","author":"Fliser","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B21","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1093\/ndt\/gfq089","article-title":"Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients","volume":"25","author":"Nasrallah","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B22","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1161\/CIRCULATIONAHA.108.844506","article-title":"Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease","volume":"119","author":"Gutierrez","year":"2009","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B23","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1093\/ndt\/gfq309","article-title":"FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment","volume":"25","author":"Seiler","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B24","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.bone.2012.02.634","article-title":"Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis","volume":"50","author":"Nakano","year":"2012","journal-title":"Bone"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B25","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1471-2369-14-112","article-title":"Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled study","volume":"14","author":"Kim","year":"2013","journal-title":"BMC Nephrol"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B26","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2215\/CJN.01040308","article-title":"Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results","volume":"3","author":"Fishbane","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B27","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2215\/CJN.03630509","article-title":"Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD","volume":"5","author":"Wetmore","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B28","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/cen.12326","article-title":"Cinacalcet treatment decreases plasma fibroblast growth factor 23 concentration in haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism","volume":"80","author":"Kuczera","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/CIRCULATIONAHA.114.013876","article-title":"Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the Evaluation Of Cinacalcet HCl Therapy To Lower Cardiovascular Events (EVOLVE) Trial","volume":"132","author":"Moe","year":"2015","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B30","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1681\/ASN.2005111194","article-title":"Relationship between moderate to severe kidney disease and hip fracture in the United States","volume":"17","author":"Nickolas","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B31","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000065222","article-title":"Risk factors for hip fracture in hemodialysis patients","volume":"22","author":"Kaji","year":"2002","journal-title":"Am J Nephrol"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B32","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ki.2013.279","article-title":"High rates of death and hospitalization follow bone fracture among hemodialysis patients","volume":"85","author":"Tentori","year":"2014","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B33","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1681\/ASN.2010121253","article-title":"Differences in bone quality in low- and high-turnover renal osteodystrophy","volume":"23","author":"Malluche","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B34","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfr317","article-title":"Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients\u2014a single-center cohort study","volume":"27","author":"Iimori","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B35","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/j.1523-1755.2005.00596.x","article-title":"Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism","volume":"68","author":"Cunningham","year":"2005","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B36","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1681\/ASN.2014040414","article-title":"Effects of cinacalcet on fracture events in patients receiving hemodialysis: the EVOLVE Trial","volume":"26","author":"Moe","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B37","doi-asserted-by":"crossref","first-page":"269","DOI":"10.5414\/CNP69269","article-title":"An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism","volume":"69","author":"Malluche","year":"2008","journal-title":"Clin Nephrol"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B38","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/ki.2014.349","article-title":"Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism","volume":"87","author":"Behets","year":"2015","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B39","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","article-title":"Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters","volume":"92","author":"Ketteler","year":"2017","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B40","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s10157-012-0665-8","article-title":"Effects of cinacalcet on bone mineral density and bone markers in hemodialysis patients with secondary hyperparathyroidism","volume":"17","author":"Tsuruta","year":"2013","journal-title":"Clin Exp Nephrol"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B41","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/ndt\/gfh829","article-title":"Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism","volume":"20","author":"Lien","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B42","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000341864","article-title":"Impact of long-term cinacalcet, ibandronate or teriparatide therapy on bone mineral density of hemodialysis patients: a pilot study","volume":"36","author":"Mitsopoulos","year":"2012","journal-title":"Am J Nephrol"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B43","first-page":"25","article-title":"Long-term effect of cinacalcet hydrochloride on abdominal aortic calcification in patients on hemodialysis with secondary hyperparathyroidism","volume":"7","author":"Nakayama","year":"2013","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B44","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1111\/j.1744-9987.2008.00629.x","article-title":"Change in coronary artery calcification score due to cinacalcet hydrochloride administration","volume":"12","author":"Tsuruta","year":"2008","journal-title":"Ther Apher Dial"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B45","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","article-title":"The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis","volume":"26","author":"Raggi","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B46","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/ndt\/gfs356","article-title":"Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study","volume":"28","author":"Urena-Torres","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B47","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B48","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/ndt\/gfq219","article-title":"Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population","volume":"26","author":"Floege","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B49","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis","volume":"359","author":"Gutierrez","year":"2008","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B50","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/ki.2010.167","article-title":"Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients","volume":"78","author":"Block","year":"2010","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B51","doi-asserted-by":"crossref","first-page":"19612","DOI":"10.1038\/srep19612","article-title":"PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism","volume":"6","author":"Akizawa","year":"2016","journal-title":"Sci Rep"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B52","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/pds.3789","article-title":"Propensity score matching and persistence correction to reduce bias in comparative effectiveness: the effect of cinacalcet use on all-cause mortality","volume":"24","author":"Gillespie","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B53","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"Chertow","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B54","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2215\/CJN.07730814","article-title":"The effects of cinacalcet in older and younger patients on hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial","volume":"10","author":"Parfrey","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B55","doi-asserted-by":"crossref","first-page":"e1001436","DOI":"10.1371\/journal.pmed.1001436","article-title":"Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials","volume":"10","author":"Palmer","year":"2013","journal-title":"PLoS Med"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B56","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1124\/mol.115.098392","article-title":"Critical cysteine residues in both the calcium-sensing receptor and the allosteric activator amg 416 underlie the mechanism of action","volume":"88","author":"Alexander","year":"2015","journal-title":"Mol Pharmacol"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B57","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/jpet.113.204834","article-title":"Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients","volume":"346","author":"Walter","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B58","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/jcph.460","article-title":"Population pharmacokinetics analysis of AMG 416, an allosteric activator of the calcium-sensing receptor, in subjects with secondary hyperparathyroidism receiving hemodialysis","volume":"55","author":"Chen","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B59","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1124\/dmd.115.068007","article-title":"Nonclinical pharmacokinetics, disposition, and drug-drug interaction potential of a novel d-amino acid peptide agonist of the calcium-sensing receptor AMG 416 (etelcalcetide)","volume":"44","author":"Subramanian","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B60","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jim.2017.03.005","article-title":"Clinical immunogenicity of the d-amino acid peptide therapeutic etelcalcetide: method development challenges and anti-drug antibody clinical impact assessments","volume":"445","author":"Kroenke","year":"2017","journal-title":"J Immunol Methods"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B61","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/jama.2016.19456","article-title":"Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B62","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jama.2016.19468","article-title":"Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180205012735_sfx125-B63","first-page":"1723","article-title":"A Phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163\/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients","volume":"32","author":"Fukagawa","year":"2017","journal-title":"Nephrol Dial Transplant"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/11\/1\/80\/23682465\/sfx125.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T01:03:44Z","timestamp":1659575024000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/11\/1\/80\/4711103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,8]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12,8]]},"published-print":{"date-parts":[[2018,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfx125","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,2]]},"published":{"date-parts":[[2017,12,8]]}}}